Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification?

Bulletin of the World Health Organization

Volumn 82, Issue 1, 2004, Pages 59-62

  Dowdle, Walter R ^a   Wolff, Christopher ^b   Sanders, Raymond ^c   Lambert, Scott ^b   Best, Maureen ^a  

^a Task Force for Child Survival and Development   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c World Health Organization ^*

Author keywords

Certification standards; Containment of biohazards methods; Laboratories standards; Laboratory infection prevention and control; Poliovirus; Poliovirus vaccine, Inactivated; Variola virus

Indexed keywords

INACTIVATED VACCINE;

DISEASE CONTROL; DISEASE SPREAD; POLIOMYELITIS; VACCINATION;

CERTIFICATION; DISEASE CONTROL; DISEASE TRANSMISSION; ERADICATION THERAPY; HUMAN; IMMUNIZATION; INFECTION RISK; OCCUPATIONAL HAZARD; POLIOMYELITIS; POLIOMYELITIS VIRUS; REVIEW; RISK FACTOR; VACCINE PRODUCTION; VIRUS SHEDDING; VIRUS TRANSMISSION;

CERTIFICATION; CHILD; DISEASE OUTBREAKS; HAZARDOUS SUBSTANCES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; LABORATORIES; LABORATORY INFECTION; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; RISK ASSESSMENT; RISK FACTORS; VIRUS SHEDDING; WORLD HEALTH ORGANIZATION;

EID: 1242295232     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. World Health Organization. Report of the Third Meeting of the Global Commission for the Certification of Eradication of Polio. Geneva: World Health Organization; 1999. WHO document WHO/EPI/GEN/981.17.
2. World Health Organization. WHO global action plan for laboratory containment of wild polioviruses, 2nd ed. Geneva: World Health Organization; 2003.
3. Dowdle WR, Gary HE, Sanders R, van Loon AM. Can post-eradication laboratory containment of wild polioviruses be achieved? Bulletin of the World Health Organization 2002;80:311-6.
4. World Health Organization. Smallpox and its eradication. Geneva: World Health Organization; 1988.
5. World Health Organization: Guidelines for implementing the pre-eradication phase of the global action plan for laboratory containment of wild polioviruses. Geneva: World Health Organization; 2000. WHO document WHO/V&B/00.21.
6. Pike RM. Laboratory-associated infections: summary and analysis of 3921 cases. Health Laboratory Science 1976;13:105-14.
7. World Health Organization. Update on actions taken following the isolation of MEF-1 reference poliovirus associated with acute flaccid paralysis cases in India in late 2002 and early 2003. Weekly Epidemiological Record 2003;78:284.
8. World Health Organization. Laboratory biosafety manual, 2nd ed (revised). Geneva: World Health Organization; 2003.
9. Mulders MN, Reimerink JHJ, Koopmans MPG, van Loon AM, van der Avoort HGAM. Genetic analysis of wild type poliovirus importation into the Netherlands (1979-1995). Journal of Infectious Diseases 1997;176:617-24.
10. World Health Organization. Guidelines for the safe production and quality control of IPV manufactured from wild polioviruses. Geneva: World Health Organization; 2003.
11. Plotkin SA, Murdin A, Vidor E. Inactivated polio vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: WB Saunders; 1999:354-63.
12. Sutter R, Cochi S, Melnick JL. Live attenuated poliovirus vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: WB: Saunders, 1999. p. 364-408.
13. Marine WM, Chin T, Gravelle CR. Limitation of fetal and pharyngeal poliovirus excretion in salk-vaccinated children, a family study during a type 1 poliomyelitis epidemic. American Journal of Nygiene 1962;76. p. 173-95.
14. Glezen WP, McCollough RH, Lamb GA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. American Journal of Epidemiology 1969;90:146-56.
15. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Martin JF. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. Journal of Infectious Diseases 1991;163:1-6.
16. World Health Organization. Guidelines on documenting the thoroughness and accuracy of conducting the laboratory survey and establishing a national inventory of laboratories retaining wild poliovirus. Geneva: World Health Organization; 2003.
17. Davies M, Bruce C, Bewley K, Outlaw M, Mioulet V, Lloyd G, et al. Poliovirus type 1 in working stocks of typed human rhinoviruses. Lancet 2003;361:1187-8.
18. Savolainen C, Hovi T. Caveat: poliovirus may be hiding under other labels. Lancet 2003;361:1145-6.